Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of dapagliflozin for the regulation of immunological activity in Membranous Nephropathy
2023-507658-34-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dapagliflozin in membranous glomerulonephritis (MGN), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Change in anti-PLA2R1 antibody titer. Planned start Sep 2025; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on 2023-507658-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507658-34-00.